Plus   Neg

AstraZeneca: IMFINZI Plus Tremelimumab Showed Promising Clinical Activity In HCC Patients

AstraZeneca Plc (AZN.L,AZN) said Friday that results from the global Phase II Study 22 trial testing the company's tremelimumab added to IMFINZI (durvalumab) demonstrated promising clinical activity and tolerability in patients with advanced hepatocellular carcinoma or HCC.

Tremelimumab is an anti-CTLA4 antibody and potential new medicine. HCC is the most common type of liver cancer.

Study 22 is an open-label, multicenter, global, four-part Phase II trial evaluating the safety and efficacy of several treatments in 433 patients with advanced HCC in the 1st- or 2nd-line setting.

AstraZeneca noted that in the primary endpoint of the trial evaluating safety, all experimental arms showed an acceptable profile and no new safety signals were identified.

Patients treated with a single, priming dose of tremelimumab 300mg added to durvalumab every four weeks (T300+D regimen) achieved a median overall survival or OS of 18.7 months in a key secondary endpoint.

The OS result for the T300+D regimen was the longest among treatments tested in the trial, which included IMFINZI monotherapy, tremelimumab monotherapy and two regimens of the two combined.

In other key secondary endpoints, objective response rate or ORR confirmed by independent central review was 24 percent with the T300+D regimen, and median duration of response or DoR was not yet reached at the time of data cut-off.

A unique T-cell profile for patients in the T300+D arm was associated with treatment response, suggesting complementary biological activity.

Kate Kelley, Associate Professor of Clinical Medicine of the Department of Medicine, University of California San Francisco, and principal investigator said, "In Study 22, we were able to induce a stronger immune response and enhance the clinical activity of IMFINZI in patients with advanced liver cancer by combining with a single dose of tremelimumab, a novel approach designed to prime the immune response using CTLA-4 inhibition at the start of therapy."

Kelley added that the results suggested dual checkpoint blockade with tremelimumab and IMFINZI may have a role in a challenging cancer where patients have few treatment options.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19. FedEx is asking NFL team Washington Redskins to change its name for its racist connotations. The delivery services company, which is a major sponsor for the team, made the suggestion following increasing pressure from its investors amid the ongoing protests against racial injustice and inequality that arose from the killing of African-American George Floyd.
Follow RTT